Key Points
- Alignment Healthcare President Dawn Christine Maroney sold 30,000 shares on May 15 at an average price of $16.09, totaling about $482,700. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Maroney still directly owned 998,813 shares, worth roughly $16.1 million. The trade reduced her ownership stake by 2.92%.
- The company recently reported stronger-than-expected quarterly results, posting $0.05 EPS versus $0.01 expected and revenue of $1.24 billion, up 33.3% year over year. Analysts currently rate the stock a Moderate Buy with an average price target of $24.60.
Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) President Dawn Christine Maroney sold 30,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $16.09, for a total value of $482,700.00. Following the sale, the president directly owned 998,813 shares of the company's stock, valued at approximately $16,070,901.17. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dawn Christine Maroney also recently made the following trade(s):
- On Wednesday, April 15th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The stock was sold at an average price of $20.87, for a total value of $626,100.00.
- On Wednesday, March 18th, Dawn Christine Maroney sold 36,749 shares of Alignment Healthcare stock. The stock was sold at an average price of $17.84, for a total value of $655,602.16.
- On Monday, March 16th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The stock was sold at an average price of $17.48, for a total value of $524,400.00.
- On Thursday, March 12th, Dawn Christine Maroney sold 29,113 shares of Alignment Healthcare stock. The stock was sold at an average price of $17.45, for a total value of $508,021.85.
Alignment Healthcare Price Performance
NASDAQ ALHC opened at $16.36 on Wednesday. Alignment Healthcare, Inc. has a 52-week low of $11.63 and a 52-week high of $23.87. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.58 and a current ratio of 1.58. The business has a 50 day simple moving average of $18.93 and a 200 day simple moving average of $19.44. The stock has a market cap of $3.38 billion, a price-to-earnings ratio of 181.78, a PEG ratio of 2.28 and a beta of 1.26.
Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.04. The company had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.22 billion. Alignment Healthcare had a net margin of 0.47% and a return on equity of 11.50%. The business's quarterly revenue was up 33.3% on a year-over-year basis. During the same period last year, the business earned ($0.05) EPS. Analysts anticipate that Alignment Healthcare, Inc. will post 0.19 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Alignment Healthcare
Several hedge funds and other institutional investors have recently made changes to their positions in ALHC. Wellington Management Group LLP grew its stake in shares of Alignment Healthcare by 167.3% in the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company's stock valued at $193,516,000 after buying an additional 6,940,277 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Alignment Healthcare by 232.5% in the first quarter. Bank of New York Mellon Corp now owns 3,313,110 shares of the company's stock valued at $58,377,000 after buying an additional 2,316,777 shares in the last quarter. Invesco Ltd. grew its stake in shares of Alignment Healthcare by 122.3% in the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company's stock valued at $58,387,000 after buying an additional 2,294,739 shares in the last quarter. Capital World Investors bought a new position in shares of Alignment Healthcare in the fourth quarter valued at $44,203,000. Finally, Loomis Sayles & Co. L P bought a new position in shares of Alignment Healthcare in the fourth quarter valued at $44,162,000. 86.19% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several brokerages have recently weighed in on ALHC. Raymond James Financial set a $22.00 price target on shares of Alignment Healthcare in a research note on Thursday, May 7th. Wall Street Zen raised shares of Alignment Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. KeyCorp reaffirmed an "overweight" rating and set a $28.00 price target on shares of Alignment Healthcare in a research note on Thursday, January 22nd. Zacks Research raised shares of Alignment Healthcare from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 28th. Finally, JPMorgan Chase & Co. raised their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $24.60.
Check Out Our Latest Research Report on ALHC
About Alignment Healthcare
(
Get Free Report)
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
